REGN•benzinga•
Regeneron Says Aflibercept 8mg Meets Primary Endpoints In 2 Global Pivotal Trials For DME And wAMD, With Vast Majority Of Patients Maintained On 12- And 16-Week Dosing Intervals
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 8, 2022 by benzinga